Evidence map›Paper›PMID 29632186›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Programmed self-assembly of peptide-major histocompatibility complex for antigen-specific immune modulation.

Chih-Ping Mao, Shiwen Peng, Andrew Yang, Liangmei He, Ya-Chea Tsai, Chien-Fu Hung, T-C Wu

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Annexin Animal Models-From Fundamental Principles to Translational Research.International journal of molecular sciences · 2021
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Chih-Ping MaoDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287.
Shiwen PengDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287.
Andrew YangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287.
Liangmei HeDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287.
Ya-Chea TsaiDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287.
Chien-Fu HungDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287.
T-C WuDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287; wutc@jhmi.edu.ORCID 0000-0003-1623-4584
Johns Hopkins University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI Richard Bruce Roden · 2003 to 2026
$53.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
Tumor Suppressor Gene Promoter Hypermethylation for Detection of Head/Neck CancerP50CA096784 · NCI · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 2002 to 2006
$11.3M
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITYR01CA114425 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, TZYY-CHOOU · 2005 to 2016
$3.0M
Molecular pathogenesis and host response following persistent E6/E7 expressionR21AI109259 · NIAID · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2014 to 2015
$446k
Innovative Strategy to Generate Antigen-Specific Cytotoxic LymphocytesR21CA194896 · NCI · JOHNS HOPKINS UNIVERSITY · PI HUNG, CHIEN-FU · 2015 to 2016
$388k
Nanog as a gateway to the immune-suppressive state in cancerF30CA177221 · NCI · JOHNS HOPKINS UNIVERSITY · PI MAO, CHIH-PING · 2013 to 2013
$47k
NCI NIH HHS F30 CA177221NCI NIH HHS P50 CA096784NCI NIH HHS P50 CA098252NCI NIH HHS R01 CA114425NCI NIH HHS R21 CA194896NIAID NIH HHS R21 AI109259NIGMS NIH HHS T32 GM007309
6 · The paper itself

Abstract

A technology to prime desired populations of T cells in the body-particularly those that possess low avidity against target antigen-would pave the way for the design of new types of vaccination for intractable infectious diseases or cancer. Here, we report such a technology based on positive feedback-driven, programmed self-assembly of peptide-major histocompatibility complex (pMHC) directly on the membrane of cognate T cells. Our design capitalizes on the unique features of the protein annexin V (ANXA5), which-in a concerted and synergistic manner-couples the early onset of TCR signaling by cognate pMHC with a surge in pMHC-TCR affinity, with repeated pMHC encounters, and with widespread TCR cross-linking. In our system, ANXA5 is linked to pMHC and firmly engages the plasma membrane of cognate T cells upon (and only upon) the early onset of TCR signaling. ANXA5, in turn, exerts a mechanical force that stabilizes interactions at the TCR-pMHC interface and facilitates repeated, serial pMHC encounters. Furthermore, ANXA5 quickly arranges into uniform 2D matrices, thereby prompting TCR cross-linking. Fusion of ANXA5 to pMHC augments lymphocyte activation by several orders of magnitude (>1,000-fold), bypasses the need for costimulation, and breaks tolerance against a model self-antigen in vivo. Our study opens the door to the application of synthetic, feedback-driven self-assembly platforms in immune modulation.

Indexed as

AnimalsAnnexin A5FemaleHistocompatibility AntigensMiceMice, TransgenicReceptors, Antigen, T-CellT-LymphocytesAnnexin A5Anxa5 protein, mouseHistocompatibility AntigensReceptors, Antigen, T-Cellannexin Vantigen-specific lymphocyteimmune modulationprotein self-assemblyT cell signaling

Identifiers

PMID29632186
PMCPMC5924900
OpenAlexW2796473836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.